??
| 中文名稱 | 轉錄因子RelB蛋白抗體 |
| 別????名 | I REL; IREL; Nuclear factor of kappa light polypeptide gene enhancer in B cells 3; RelB; Reticuloendotheliosis viral oncogene homolog B; Transcription factor RelB; v rel avian reticuloendotheliosis viral oncogene homolog; v rel reticuloendotheliosis viral oncogene homolog B; RELB_HUMAN; I-Rel.?? |
| 研究領域 | 腫瘤??免疫學??信號轉導??細胞凋亡??轉錄調節因子?? |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human,?Mouse,? (predicted: Rat,?Dog,?Pig,?Cow,?Horse,?) |
| 產品應用 | WB=1:500-2000?ELISA=1:500-1000?IHC-P=1:100-500?IHC-F=1:100-500?Flow-Cyt=1:20-100?IF=1:100-500?(石蠟切片需做抗原修復) not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分?子?量 | 64kDa |
| 細胞定位 | 細胞核?細胞漿? |
| 性????狀 | Liquid |
| 濃????度 | 1mg/ml |
| 免?疫?原 | KLH conjugated synthetic peptide derived from human RelB:161-260/579? |
| 亞????型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲?存?液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| PubMed | PubMed |
| 產品介紹 | The NFKB complex consists of NFKB1 or NFKB2 bound to REL, RELA, or RELB. The NFKB complex is inhibited by I kappa B proteins (NFKBIA, or NFKBIB), which inactivate NF kappa B by trapping it in the cytoplasm. Phosphorylation of serine residues on the I kappa B proteins by kinases (IKBKA, or IKBKB,) marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NF kappa B complex. Function: NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Subunit: Component of the NF-kappa-B RelB-p50 complex. Component of the NF-kappa-B RelB-p52 complex. Self-associates; the interaction seems to be transient and may prevent degradation allowing for heterodimer formation with p50 or p52. Interacts with NFKB1/p50, NFKB2/p52 and NFKB2/p100. Interacts with NFKBID. Subcellular Location: Nucleus. Cytoplasm, cytoskeleton, centrosome. Note=Co-localizes with NEK6 in the centrosome. Post-translational modifications: Phosphorylation at 'Thr-103' and 'Ser-573' is followed by proteasomal degradation. Similarity: Contains 1 RHD (Rel-like) domain. SWISS: Q01201 Gene ID: 5971 Database links: Entrez Gene: 5971?Human Omim: 604758?Human SwissProt: Q01201?Human Unigene: 654402?Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. ? |
| 產品圖片 | Sample: Spleen (Mouse) Lysate at 40 ugPrimary: Anti-RelB (bs-4185R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 64 kD Observed band size: 64 kD Sample:Raji Cell (Human) Lysate at 30 ug Primary: Anti-RelB (bs-4185R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 64 kD Observed band size: 64 kD Paraformaldehyde-fixed, paraffin embedded (human colon carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (RelB) Polyclonal Antibody, Unconjugated (bs-4185R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining. Sample: mouse bloodprimary antibody: Anti-RelB/PE-Cy5(bs-4185R-PE-Cy5). concentration:1:20, 4℃ incubate 30min. |

Sample: Spleen (Mouse) Lysate at 40 ug
Sample:
Paraformaldehyde-fixed, paraffin embedded (human colon carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (RelB) Polyclonal Antibody, Unconjugated (bs-4185R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Sample: mouse blood